Stone Ridge Asset Management LLC acquired a new stake in Eli Lilly and Co (NYSE:LLY) in the 4th quarter, Holdings Channel reports. The firm acquired 26,360 shares of the company’s stock, valued at approximately $2,226,000.
Several other large investors also recently added to or reduced their stakes in LLY. Vanguard Group Inc. grew its position in Eli Lilly and by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after purchasing an additional 1,610,885 shares during the period. BlackRock Inc. grew its position in Eli Lilly and by 1.2% in the 4th quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock valued at $5,393,119,000 after purchasing an additional 776,893 shares during the period. Franklin Resources Inc. grew its position in Eli Lilly and by 2.7% in the 4th quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock valued at $2,408,787,000 after purchasing an additional 754,681 shares during the period. Janus Henderson Group PLC grew its position in Eli Lilly and by 16.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after purchasing an additional 1,503,918 shares during the period. Finally, Geode Capital Management LLC grew its position in Eli Lilly and by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock valued at $830,522,000 after purchasing an additional 406,812 shares during the period. Institutional investors own 77.58% of the company’s stock.
Eli Lilly and Co (LLY) opened at $79.04 on Tuesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32. The stock has a market cap of $87,220.55, a price-to-earnings ratio of -395.18, a price-to-earnings-growth ratio of 1.48 and a beta of 0.28. Eli Lilly and Co has a fifty-two week low of $73.69 and a fifty-two week high of $89.09.
Several analysts recently issued reports on the stock. BMO Capital Markets lifted their price target on shares of Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a research report on Thursday, February 1st. Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. JPMorgan Chase & Co. set a $105.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Morgan Stanley lifted their price target on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 21st. Finally, TheStreet downgraded shares of Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $93.47.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the completion of the transaction, the senior vice president now directly owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders sold a total of 212,261 shares of company stock worth $18,627,485 over the last three months. 0.20% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3259626/stone-ridge-asset-management-llc-takes-2-23-million-position-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.